Cyclopharm (ASX:CYC) Presentation, FNN Investor Event, September 2018, Sydney

Company Presentations

Cyclopharm (ASX:CYC) Managing Director & CEO, James McBrayer presents an update on its radiopharmaceutical products used in imaging, sales of Technegas and its US FDA application at FNN's Investor Event.

Key points:

- Cyclopharm Limited (ASX:CYC) is a leading diagnostic lung imaging company
- Profitable & Growing MedTech
- USA FDA approval set to increase growth
- First in class technology in the 56 countries
- 4M Technegas patient scans
- Opportunity to broaden Technegas applications beyond pulmonary embolism diagnosis

For more infortmation, watch Managing Director & CEO James McBrayer present.